Risk of underdosing of ampicillinsulbactam in patients with acute kidney injury undergoing extended daily dialysis - A single case

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2283-2285

  Kielstein, Jan T ^a   Lorenzen, Johan ^a   Kaever, Volkhard ^a   Burhenne, Heike ^a   Broll, Michael ^a   Hafer, Carsten ^a   Burkhardt, Olaf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Beta lactamase inhibitor; Dialysis; Genius dialysis; Pharmacokinetics

Indexed keywords

POLYSULFONE; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; SULBACTAM;

ACUTE DISEASE; ACUTE KIDNEY INJURY; AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; EXTENDED DAILY DIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ACUTE KIDNEY FAILURE; ENTEROCOCCUS FAECALIS; GRAM POSITIVE INFECTION; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; RENAL DIALYSIS; RISK FACTORS; SULBACTAM; URINARY TRACT INFECTIONS;

EID: 67651114066     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp060     Document Type: Article

References (10)

1. Lode HM. Rational antibiotic therapy and the position of ampicillin/sulbactam. Int J Antimicrob Agents 2008; 32: 10-28
2. Blum RA, Kohli RK, Harrison NJ et al. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989; 33: 1470-1476
3. Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2: 32-39
4. Burkhardt O, Joukhadar C, Traunmuller F et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61: 224-225
5. Burkhardt O, Hafer C, Langhoff A et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24: 267-271
6. Czock D, Husig-Linde C, Langhoff A et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1: 1263-1268
7. Fiaccadori E, Maggiore U, Rotelli C et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006; 21: 1402-1406
8. Kielstein JT, Czock D, Schopke T et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51-56
9. Dager WE. Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 2006; 34: 240-241
10. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27: 808-814